Gil Wolfe joins Nils Erik Gilhus to discuss thymectomy in people with MG, with a focus on indications, patient selection, and optimal timing. They reflect on which people with AChR-positive generalized MG are likely to benefit from surgery, how age and disease subtype influence surgical decision-making, and why timing, minimally invasive surgery, and close neurologist–surgeon collaboration are critical to optimizing outcomes.

Episode 20 – John Vissing discusses what patients with MG often leave unsaid in clinic, including why symptoms may not be volunteered without targeted questioning, how patients prioritize functional impact over measured muscle strength, and the hidden psychological burden that shapes treatment satisfaction. Drawing on survey data and clinical experience, the discussion highlights how asking the right questions can reveal unmet needs, fears of exacerbation, and concerns that rarely surface unprompted.

Episode 19 – Henry Kaminski and Nils Erik Gilhus reflect on how MG care has evolved. From the impact of targeted therapies, such as complement and FcRn inhibitors, to breakthroughs on the horizon, they unpack why patients are doing better today, the challenges that remain, and whether emerging strategies could lead to lasting remission.

Episode 18 – Digital innovation is transforming the way we manage MG. Henry Kaminski joins Nils Erik Gilhus to discuss the role of AI, remote monitoring, and patient-driven tools in shaping future care. Kaminski shares insights on how these technologies can improve disease tracking, strengthen patient–clinician interaction, and support the delivery of expert care across fragmented health systems.

Episode 17 - Tobias Ruck joins Nils Erik Gilhus to share his experience managing a compelling case involving a patient with recurrent crises and respiratory failure. Together, they discuss how to identify early red flags and emphasize the importance of timely intervention before respiratory compromise becomes critical.

Episode 16 – Professor Nils Erik Gilhus welcomes Professor Francesco Saccà to discuss quality of life in people with MG, including the outsized impact of unpredictable symptoms, striking the right balance when informing patients about the risk of myasthenic crisis, and how encouraging patients to regularly self-report symptoms can influence both wellbeing and treatment planning.

Episode 15 – Professor Francesco Saccà joins Professor Nils Erik Gilhus to delve into the pathophysiology of MG, discussing the role of the complement system, what determines whether MG is a fully reversible disease, and the necessity of accurate biomarkers for personalised care. They also discuss the different contributions of T and B cells to MG and how these may impact the success of targeted treatments.

Episode 14 – Cell-based diagnostic assays now available for MG are more sensitive than previous assays, but “are they as specific?” Professor Nils Erik Gilhus and Dr Gregorio Spagni discuss sensitivity and specificity of these new assays, as well as cost and ease of use.

Episode 13 – Professor Jan De Bleecker joins Professor Nils Erik Gilhus to reflect on EAN 2024 and discuss key congress highlights, including information on therapeutic advances in MG.

Professor Nils Erik Gilhus welcomes Professor Ernestina Santos to discuss late-onset MG, including the definition of late onset versus early onset, diagnostic and treatment challenges, and physical activity recommendations for these patients.